Boston Scientific, Scivita Team Up on Endoscopic Devices

Boston Scientific and Chinese firm Scivita Medical Technology announced they have signed an expanded strategic cooperation agreement, which will focus on endoscopic technology.
 
Scivita offers minimally invasive diagnosis and treatment solutions, focusing on research, development, and commercialization of medical endoscopes and related products. The company has R&D centers in China and Japan. Its technology platform is built on five synergistic core technologies, with a portfolio of endoscope and therapeutic products covering endoscope procedures in various clinical departments.
 
Under the arrangement, Scivita is expanding its partnership with Boston Scientific for co-development and global distribution activities. These may include collaborating on development of future endoscopic devices, as well as global distribution of Scivita’s single-use endoscope and imaging devices, according to the companies.
 
The duo expects the expanded arrangement to help bring Scivita products to more hospitals and patients in China and other global geographies.
 
“We are excited to further our relationship with Scivita Medical which we anticipate will help provide physicians with more device options in geographies around the world,” said Mike Jones, senior VP and president, Endoscopy, Boston Scientific. “We look forward to successfully building on that relationship with this new arrangement.”
 
“I am delighted to announce the deepened collaboration between Scivita Medical and Boston Scientific, a leading global medical technology company,” added Dr. Chin To, Scivita’s co-founder, GM, and chief technology officer. “This strengthened relationship will help us combine our core strengths and expertise to deliver high-quality single-use endoscope solutions to doctors and patients in various regions across the globe. Working with a company like Boston Scientific is crucial to Scivita Medical’s globalization strategy. We will continue to focus on innovative research and development, expand our business cooperation models, and provide more innovative, high-quality, and accessible products to benefit doctors and patients worldwide,” said that Dr. Chin To, Co-founder, General Manager, and Chief Technology Officer of Scivita Medical.
 
Earlier this month, Boston Scientific gained U.S. Food and Drug Administration (FDA) approval for its Agent drug-coated balloon to treat coronary in-stent restenosis for coronary disease patients.